Palladium Capital Advisors advises on Amarin Corp PLC´s $17.8M Placement
May 25, 2005 Amarin Corporation plc (NASDAQSC: AMRN) today announced that it has completed its previously announced registered direct offering with institutional and other accredited investors for gross proceeds of $17.8 million. The financing is intended to strengthen Amarin´s balance sheet and to provide funding for clinical trials. Miraxion, Amarin´s lead development compound, is in phase III development for Huntington´s disease and in phase II development for treatment of unresponsive depression. Palladium Capital Advisors acted as a consultant to ProSeed Capital Holdings, which served as placement agent for Amarin Corp.
Copyright 2003-2010 © Palladium Capital Advisors, LLC Member FINRA/SIPC